| First Author | Wang YN | Year | 2018 |
| Journal | Cancer Cell | Volume | 33 |
| Issue | 4 | Pages | 752-769.e8 |
| PubMed ID | 29606349 | Mgi Jnum | J:260705 |
| Mgi Id | MGI:6150967 | Doi | 10.1016/j.ccell.2018.02.012 |
| Citation | Wang YN, et al. (2018) Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell 33(4):752-769.e8 |
| abstractText | Pancreatic ribonuclease (RNase) is a secreted enzyme critical for host defense. We discover an intrinsic RNase function, serving as a ligand for epidermal growth factor receptor (EGFR), a member of receptor tyrosine kinase (RTK), in pancreatic ductal adenocarcinoma (PDAC). The closely related bovine RNase A and human RNase 5 (angiogenin [ANG]) can trigger oncogenic transformation independently of their catalytic activities via direct association with EGFR. Notably, high plasma ANG level in PDAC patients is positively associated with response to EGFR inhibitor erlotinib treatment. These results identify a role of ANG as a serum biomarker that may be used to stratify patients for EGFR-targeted therapies, and offer insights into the ligand-receptor relationship between RNase and RTK families. |
